Danazol
Authors:
- 1 May 1982
- journal article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 96 (5) , 625-630
Abstract
Danazol, approved 5 years ago for the treatment of pelvic endometriosis, has recently been approved for treating cystic disease of the breast. As the mechanisms of action of this drug are made clear, the clinical syndromes that can be treated by this impeded androgen have increased dramatically. Results of controlled prospective clinical studies on the drug have increased our understanding of the pathophysiology of several poorly understood diseases. Danazol is well tolerated by most patients; the side effects are mild and reversible.Keywords
This publication has 60 references indexed in Scilit:
- Dosage aspects of danazol therapy in endometriosis: Short-term and long-term effectivenessAmerican Journal of Obstetrics and Gynecology, 1981
- Danazol binding and translocation of steroid receptorsAmerican Journal of Obstetrics and Gynecology, 1980
- Prophylaxis of attacks of hereditary angioedemaThe American Journal of Medicine, 1979
- A double blind trial of the prolactin inhibitor bromocriptine in painful benign breast diseaseBritish Journal of Surgery, 1978
- Progestational activity of Danazol in the human female subjectAmerican Journal of Obstetrics and Gynecology, 1976
- Danazol: An antigonadotropic agent in the treatment of pelvic endometriosisAmerican Journal of Obstetrics and Gynecology, 1975
- Successful treatment of mastodynia with the prolactin inhibitor bromocryptine (CB 154)Archives of Gynecology and Obstetrics, 1975
- Malignant and benign human mammary disease: Estrogen binding in relation to clinical dataCancer, 1974
- Enovid therapy (norethynodrel with mestranol) for fibrocystic diseaseAmerican Journal of Obstetrics and Gynecology, 1973
- A biochemical abnormality in hereditary angioneurotic edemaThe American Journal of Medicine, 1963